POST Online Media Lite Edition



 

Teva agrees to pay $54m fine to settle whistleblower lawsuit

Christian Fernsby |
Teva Pharmaceuticals USA and two subsidiaries agreed to pay $54 million to settle allegations in a whistleblower lawsuit that the company improperly paid physicians to serve as speakers or consultants to boost prescriptions for two Teva products.

Article continues below



Topics: TEVA    FINE    WHISTLEBLOWER    LAWSUIT   

The settlement was announced by the Philadelphia law firm McEldrew Young and Shepherd, which along with the firm Finkelman, Miller and Shah, also of Philadelphia, represented two former Teva sales representatives in the matter.

According to the lawsuit filed in 2013, Teva allegedly induced doctors to write prescriptions for the drugs Copaxone and Azilect, and influenced other doctors to do the same, by paying them as "speakers" or "consultants." Many of the speaker programs, according to the complaint, were "sham events." Copaxone is a multiple sclerosis treatment. Azilect is a Parkinson's disease drug.


What to read next

Teva to pay $519 million to settle bribery charges
TechnipFMC and U.S. subsidiary to pay over $296 million to resolve foreign bribery case
Odebrecht and Braskem to pay $3.5bn in largest global foreign bribery case